Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending September 30, 2022 was $-42.5 Million (a -27.76% decrease compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 139.16%
- Annual Consolidated Net Income/Loss for 2021 was $-184 Million (a 0.68% increase from previous year)
- Annual Consolidated Net Income/Loss for 2020 was $-183 Million (a 67.88% increase from previous year)
- Annual Consolidated Net Income/Loss for 2019 was $-109 Million (a 7.55% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending September 30, 2022 was $-193 Million (a -7.77% decrease compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss increased by 5.05% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| $-193 Million | $-210 Million | $-194 Million | $-184 Million |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of BioCryst Pharmaceuticals, Inc.
Most recent Consolidated Net Income/Lossof BCRX including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $-42.52 | $-58.86 | $-74.2 | – |
| 2021 | $-17.78 | $-58.8 | $-43.2 | $-64.28 | $-184.06 |
| 2020 | $-60.49 | $-46.12 | $-38.61 | $-37.6 | $-182.81 |
| 2019 | $-2.62 | $-37.59 | $-37.63 | $-31.05 | $-108.9 |
| 2018 | $-27.43 | $-29.6 | $-18.45 | $-25.78 | $-101.25 |
| 2017 | $-19.54 | $-15.13 | $-16.89 | $-14.22 | $-65.78 |
| 2016 | $-4.5 | $-11.53 | $-16.28 | $-22.83 | $-55.14 |
| 2015 | $-18.14 | $-14.62 | $4.9 | $-15.16 | $-43.02 |
| 2014 | $-11.67 | $-8.73 | $-14.65 | $-10.14 | $-45.19 |
| 2013 | $-5.43 | $-8.0 | $-12.17 | $-4.51 | $-30.11 |
| 2012 | $-11.05 | $-9.7 | $-12.28 | $-6.05 | $-39.08 |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology